INTRODUCTION AND OBJECTIVES: Currently, penile cancer patients with impalpable inguinal lymph nodes routinely undergo dynamic sentinel node biopsy (DSNB) to diagnose metastatic spread to the inguinal basin. Those with positive DSNB are then offered completion inguinal lymph node dissection (ILND). Given the high morbidity associated with ILND we set out to identify factors within the positive sentinel node that may help to predict those at highest risk of having metastases at ILND. METHODS: Patients who had undergone completion ILND following positive DSNB were identified retrospectively from the penile cancer databases of two high volume European centers. Four potential predictive covariates were analysed; size of the largest positive sentinel node (SL), size of the largest area of metastasis within a positive lymph node (SM), percentage of lymph node replaced by cancer (PM), and extracapsular spread (ECS). ROC curve analysis of each covariate was used to assess strength as a test, and identify a cut-off value for regression analysis. Odds ratios were derived using logistic binary regression. Statistical analysis was performed using IBM SPSS 25.
RESULTS: Between November 2004 and November 2017 (Centre 1) and February 1994 and June 2016 (Centre 2) 279 patients underwent 304 completion ILND following positive sentinel node biopsy. Complete data was available for 287. The mean number of sentinel nodes sampled from each groin was 2.21 of which a mean of 1.24 were positive, which was similar for those with positive and negative ILND. Of the variables tested SL did not show any correlation to ILND positivity, but SM, PM and ECS did. When SM was stratified into three groups by increasing size a clear trend was demonstrated with increasing size showing an increasing percentage of patients having positive nonsentinel nodes. ROC curve analysis derived cut-offs of 6.25mm for SM, and 32% for PM. Odds ratio of having a positive ILND with SM>6.25 was 2.09 (p[0.012), with PM>32% it was 2.81 (p[0.001), and with ECS positive it was 1.8 (p[0.081).
CONCLUSIONS: Completion groin dissection following positive DSNB is a procedure with a high level of associated morbidity. By using the predictive factors we have identified within a positive sentinel node we can identify those patients who are more likely to have non-sentinel node metastases. This will allow a better informed discussion with our patients regarding the need for further surgery.
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MP49-18 NATIONAL MANAGEMENT TRENDS IN CLINICAL STAGE IIA NON-SEMINOMATOUS GERM CELL TUMOR (NSGCT) AND OPPORTUNITIES TO AVOID DUAL THERAPY
Ryan Werntz*, Craig Labbate, Vignesh Packiam, Scott Eggener, Chicago, IL INTRODUCTION AND OBJECTIVES: Retroperitoneal lymph node dissection (RPLND; NCCN category 2a) or chemotherapy (NCCN category 2b) are recommended as first line treatment for clinical stage (CS) IIA NSGCT and are both associated with excellent long-term survival. RPLND cures 70-90% of pN1 patients, eliminating the need for chemotherapy and the potential associated morbidity. Therefore, surveillance is the preferred option after RPLND for pN1 patients. We aimed to determine national practice patterns in the management of CSIIA NSGCT and adherence to NCCN guidelines.
METHODS: The National Cancer Data Base (NCDB) was used to identify 1,547 men diagnosed with CSIIA NSGCT with negative serum tumor markers between 2004 and 2016. Trends in the utilization of initial and adjuvant treatment [(chemotherapy only, RPLND only, RPLND with adjuvant chemotherapy (all receiving both chemotherapy and RPLND), and post chemotherapy RPLND)] were analyzed. Opportunities to avoid chemotherapy were analyzed according to final pathologic N stage (pN).
RESULTS: Of the 1,547 men with clinical stage IIA, 18% (273) had RPLND alone, 51% (786) chemotherapy alone, 28% (438) RPLND and adjuvant chemotherapy, and 3% (50) had a post chemotherapy RPLND. In patients with RPLND alone, 32% (88) were pN0, 57% (155) were pN1, 9.5% (26) pN2, and 1.5% (26) pN3. In the RPLND and adjuvant chemotherapy group, 25% (110) were pN0, 59.8% (262) were pN1, 13.2% (58) were pN2, and 1.8% (58) were pN3. There was no association between National Cancer Institute (NCI) status and deliverance of non-guideline based adjuvant chemotherapy (p[0.35) CONCLUSIONS: Induction chemotherapy as first line treatment in clinical stage IIA NSGCT patients was the most common treatment choice despite NCCN guidelines recommending RPLND as the preferred option. In the RPLND and adjuvant chemotherapy group, 85% of patients were pN1 or less yet all received additional chemotherapy, despite surveillance being the preferred NCCN option.
